Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 16, 2023
Next generation radiotheranostics promoting precision medicine
K L Pomykala, B A Hadaschik, O Sartor, et al.
Oncogene
|
February 16, 2016
Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer
D Zheng, B Gui, K P Gray, et al.
Cancer
|
August 3, 1999
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium
C J Sweeney, S D Williams, D E Finch, et al.
Cancer
|
December 18, 2001
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma
C J Sweeney, J Zhu, A B Sandler, et al.
Oncogene
|
June 18, 2013
MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A
T Sun, X Wang, H H He, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2015
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
E G Chiorean, H I Hurwitz, R B Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2002
A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer
C J Sweeney, F J Monaco, S H Jung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2009
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67
N M Hahn, R T Zon, M Yu, et al.
Carcinogenesis
|
February 5, 2000
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
M T Yip-Schneider, D S Barnard, S D Billings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2015
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion
C A Lago-Hernandez, H Feldman, E O'Donnell, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 16, 2023
Next generation radiotheranostics promoting precision medicine
K L Pomykala, B A Hadaschik, O Sartor, et al.
Oncogene
|
February 16, 2016
Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer
D Zheng, B Gui, K P Gray, et al.
Cancer
|
August 3, 1999
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium
C J Sweeney, S D Williams, D E Finch, et al.
Cancer
|
December 18, 2001
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma
C J Sweeney, J Zhu, A B Sandler, et al.
Oncogene
|
June 18, 2013
MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A
T Sun, X Wang, H H He, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2015
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
E G Chiorean, H I Hurwitz, R B Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2002
A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer
C J Sweeney, F J Monaco, S H Jung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2009
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67
N M Hahn, R T Zon, M Yu, et al.
Carcinogenesis
|
February 5, 2000
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
M T Yip-Schneider, D S Barnard, S D Billings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2015
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion
C A Lago-Hernandez, H Feldman, E O'Donnell, et al.
Page
of 5